Access cutting-edge head and neck cancer treatment through this phase 1 clinical trial at a research site in Chapel Hill. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Chapel Hill location
Preparing your pre-screening questions…
Access head and neck cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related head and neck cancer treatment provided free
Check if you qualify for this head and neck cancer clinical trial in Chapel Hill, NC
No-Cost Study Care
Local to Chapel Hill
Convenient for NC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cancer that came back after receiving standard therapy for this cancer. The iC9.CAR-CSPG4 treatment is experimental and has not been approved by the Food and Drug Administration. How many (dose) of the iC9.CAR. CSPG4 T cells are safe to use in patients without causing too many side effects, and what is the maximum dose that could be tolerated will be investigated. The information collected from the study would help cancer patients in the future. There are two parts to this study. In part 1, blood will be collected to prepare the iC9.CAR-CSPG4 T cells. Disease fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells. In part 2, the iC9.CAR-CSPG4 T cells are given by infusion after completion of lymphodepletion chemotherapy. The data from the dose escalation will be used to determine a recommended phase 2 dose (RP2D), which will be decided based on the maximum tolerated dose (MTD). Additionally, recommended phase 2 dose will be tested. Eligible subjects will receive lymphodepletion chemotherapy standard followed by infusion of iC9-CAR.CSPG4 T cells. After treatment completion or discontinuation, subjects will be followed since involving gene transfer experiments.
Sponsor: UNC Lineberger Comprehensive Cancer Center
Yes, this clinical trial (NCT06096038) has an active research site in Chapel Hill, NC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for head and neck cancer treatment options in Chapel Hill, NC, this clinical trial (NCT06096038) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chapel Hill research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced head and neck cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all head and neck cancer clinical trials near you to find additional studies recruiting in your area.
See all head and neck cancer clinical trials recruiting in Chapel Hill — not just this study.
Browse Head and Neck Cancer Trials in Chapel Hill →